SAN DIEGO, October 3, 2017 /PRNewswire/ --
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB:RGBPP) scientists have used a standard biochemical assay to determine if some of its small molecules that have been shown to activate NR2F6 in cells, physically interact with NR2F6 in vitro. The Company reports that the experiments indicate that some
The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 program at Regen aims to identify antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system as well as identifying agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity.
"We have used a well-known biochemical assay, termed a thermal shift assay, to examine whether our drugs in development bind directly to NR2F6. We were delighted to see clear evidence of binding," says Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen. "Although this specific assay does not tell us how tightly the drugs bind, it does tell us that binding is occurring. We are preparing another assay to answer the questions about affinity."
"It may sound pedestrian, but this is very important new information," says David Koos, Ph.D., Chairman & CEO Regen BioPharma Inc. "It confirms all of our prior suppositions about mechanism, and gives us great confidence in our program moving forward."
About Regen BioPharma Inc.:
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/II clinical trials. Currently, the Company is focused on small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Contact Information Regen BioPharma Inc. David R. Koos, Ph.D. Chairman & Chief Executive Officer +1-619-702-1404 Phone +1-619-330-2328 Fax [email protected]http://www.regenbiopharma.com
SOURCE Regen BioPharma, Inc.
Subscribe to our Free Newsletters!
Sea food allergy is the adverse response of the body''s immune system to the proteins present in ...
Yellow fever is a hemorrhagic fever that is transmitted by infected mosquitoes and it can lead to ...
Routes of drug administration play a major role in a medical treatment. Selecting a right route of ...View All